Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS‐CoV ‐2

Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS‐CoV ‐2

Antiviral monoclonal antibody (mAb) discovery enables the development of antibody-based antiviral therapeutics. Traditional antiviral mAb discovery relies on affinity between antibody and a viral antigen to discover potent neutralizing antibodies, but these approaches are inefficient because many hi...

Full description

Bibliographic Details
Main Authors: Madan, Bharat, Reddem, Eswar R., Wang, Pengfei, Casner, Ryan G., Nair, Manoj S., Huang, Yaoxing, Fahad, Ahmed S., Souza, Matheus Oliveira, Banach, Bailey B., López Acevedo, Sheila N., Pan, Xiaoli, Nimrania, Rajani, Teng, I‐Ting, Bahna, Fabiana, Zhou, Tongqing, Zhang, Baoshan, Yin, Michael T., Ho, David D., Kwong, Peter D., Shapiro, Lawrence, DeKosky, Brandon J.
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering
Format: Article
Language:English
Published: Wiley 2022
Online Access:https://hdl.handle.net/1721.1/140317

Internet

https://hdl.handle.net/1721.1/140317

Similar Items